Romosozumab vs Bisphosphonates for Osteogenesis Imperfecta

Recruiting at 69 trial locations

Overseen By Amgen Call Center

Age: < 18

Sex: Any

Trial Phase: Phase 3

Sponsor: Amgen

Disqualifiers: Electrophoresis pattern, Gene mutation, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

Duration: 12 months

106 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests two treatments for osteogenesis imperfecta (OI), a condition that causes bones to break easily. Researchers aim to determine if romosozumab, administered once a month for a year, outperforms standard bisphosphonate treatments (drugs that prevent bone density loss) in preventing fractures and improving bone density. The trial is suitable for children and teens who can walk, even with assistance, and have experienced several fractures in the past two years. Participants should have a clinical history of specific types of OI, identifiable by features like blue sclera (blue-tinted whites of the eyes) or frequent bone breaks. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that romosozumab is generally safe. The FDA has approved it for treating osteoporosis in postmenopausal women, confirming its safety for that use. Past studies demonstrated that romosozumab significantly improves bone density, strengthening bones.

Some people reported side effects like joint pain and headaches, but these are uncommon. Most participants in these studies did not experience serious problems. Bisphosphonates have treated bone issues for many years. They are usually safe but can sometimes cause stomach upset or bone pain.

In summary, both treatments have a good safety record. However, discussing any concerns with a doctor is always important. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for osteogenesis imperfecta?

Most treatments for osteogenesis imperfecta, like bisphosphonates, work by slowing down bone loss. But romosozumab works differently, targeting a protein called sclerostin to both increase bone formation and decrease bone breakdown. Researchers are excited about romosozumab because it offers a dual action that could potentially lead to stronger bones more quickly than current treatments. Plus, it's administered just once a month, which might be more convenient for patients compared to the frequent dosing of traditional options.

What evidence suggests that this trial's treatments could be effective for osteogenesis imperfecta?

This trial will compare Romosozumab with Bisphosphonates for treating Osteogenesis Imperfecta. Research has shown that Romosozumab can greatly improve bone strength in people with osteoporosis, a condition where bones become weak. Studies found that patients using Romosozumab experienced a significant increase in bone strength in the spine and hip. Additionally, markers indicating new bone growth increased, while markers showing bone breakdown decreased after 12 months of treatment. These results suggest that Romosozumab could help strengthen bones and lower the risk of fractures. While Bisphosphonates are commonly used to improve bone strength, Romosozumab offers a promising alternative because it helps build new bone. Participants in this trial will receive either Romosozumab or Bisphosphonates as part of separate treatment arms. ^{1 2 4 6 7}

Who Is on the Research Team?

MD

Principal Investigator

Amgen

Are You a Good Fit for This Trial?

This trial is for children and adolescents aged 5 to less than 18 with Osteogenesis Imperfecta (OI), a condition that makes bones fragile. Participants must have had at least three fractures in the past two years or one nonvertebral fracture plus a vertebral fracture, or two vertebral fractures. They need a lumbar spine Z-score of ≤-1.0 and must be able to walk, with assistance if necessary.

Inclusion Criteria

I have had 3 or more fractures in the last 2 years or at least 1 non-spine fracture and 1 spine fracture.

My family's condition is passed down directly from one parent.

Participant has provided informed consent/assent prior to initiation of any study specific activities/procedures

Exclusion Criteria

I have current oral infections that are not treated or healed.

Current hypocalcemia (albumin-adjusted serum calcium <lower limit of normal [LLN]) or hypercalcemia (albumin-adjusted serum calcium > upper limit of normal [ULN] of the laboratory's reference range)

Parathyroid hormone (PTH) or PTH derivatives within 12-months prior to screening

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either romosozumab once a month or bisphosphonates per local standard of care for 12 months

12 months

Monthly visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months

1-2 visits (in-person)

Extension

Participants may continue to be monitored for treatment-emergent adverse events

3 months

What Are the Treatments Tested in This Trial?

Interventions

• Bisphosphonate
• Romosozumab

Trial Overview

The study compares Romosozumab with Bisphosphonates over 12 months to see which treatment better reduces the number of bone fractures in kids with OI. It also looks at changes in bone density after six months. The goal is to find out if Romosozumab can improve bone strength more effectively than current treatments.

How Is the Trial Designed?

Group I: Romosozumab Experimental Treatment 1 Intervention

Participants will receive romosozumab once a month (QM) for 12 months.

Group II: Standard of Care Bisphosphonate Active Control 1 Intervention

Participants will receive bisphosphonates per local standard of care treatment regimens, as determined by the investigator for 12 months.

Bisphosphonate is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:

Approved in European Union as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• High calcium levels in cancer patients
• Bone metastases

Approved in United States as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• Glucocorticoid-induced osteoporosis
• High calcium levels in cancer patients
• Bone metastases

Approved in Canada as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• High calcium levels in cancer patients
• Bone metastases

Approved in Japan as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• High calcium levels in cancer patients
• Bone metastases

Approved in China as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• High calcium levels in cancer patients
• Bone metastases

Approved in Switzerland as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• High calcium levels in cancer patients
• Bone metastases

Who Is Running the Clinical Trial?

Amgen

Lead Sponsor

Trials

1,508

Recruited

1,433,000+

Founded

1980

Headquarters

Thousand Oaks, USA

Known For

Human Therapeutics

Top Products

Enbrel, Prolia, Neulasta, Otezla

Robert A. Bradway

Amgen

Chief Executive Officer since 2012

MBA from Harvard Business School

Paul Burton

Amgen

Chief Medical Officer since 2023

MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London

Published Research Related to This Trial

Oral bisphosphonates, commonly used for osteoporosis, can cause various adverse events including gastrointestinal issues, musculoskeletal pain, and osteonecrosis of the jaw, while intravenous bisphosphonates are linked to similar issues but with added risks of renal toxicity.

The severity and frequency of adverse events from bisphosphonates are often related to the dosage and potency of the medication, highlighting the need for careful management in their use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bisphosphonate-associated adverse events. Papapetrou, PD.[2022]

A study analyzing 1692 reports of atypical femur fractures (AFF) found that several anti-osteoporosis drugs, including alendronate and denosumab, are associated with an increased risk of AFF, with alendronate showing the highest risk signal.

The analysis indicated that while alendronate, denosumab, and other bisphosphonates had significant risk signals for AFF, drugs like raloxifene and romosozumab did not show any association, suggesting varying safety profiles among osteoporosis treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. Xiao, Y., Chen, Y., Huang, Y., et al.[2023]

In a study of 90 adults with osteogenesis imperfecta (OI), bisphosphonate treatment, particularly intravenous pamidronate, significantly increased bone mineral density (BMD) in type I and type III/IV patients over an average treatment duration of 52 months.

While bisphosphonates improved BMD, they did not reduce fracture rates in type I OI patients, and only pamidronate treatment led to a decrease in fracture rates for type III/IV patients, suggesting that bisphosphonate therapy may not be suitable for all OI adults.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Shapiro, JR., Thompson, CB., Wu, Y., et al.[2018]

In a study of 161 children and adolescents with osteogenesis imperfecta, both intravenous zoledronic acid (ZOL) and oral alendronate (ALN) were effective in increasing bone mineral density (BMD), with ZOL showing a slightly higher increase in Z-scores.

ZOL was significantly more effective than ALN in reducing the clinical fracture rate, indicating it may provide better long-term safety and efficacy for patients with osteogenesis imperfecta.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY. Lv, F., Liu, Y., Xu, X., et al.[2021]

A study involving 20 children with osteogenesis imperfecta (OI) showed that daily alendronate therapy significantly improved vertebral bone mineral density and quality of life markers after one year, with most improvements noted in self-care and well-being scores.

Alendronate was well tolerated with minimal side effects, indicating it is a safe and effective treatment option for enhancing bone health and quality of life in children with OI.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Impact of alendronate on quality of life in children with osteogenesis imperfecta. Seikaly, MG., Kopanati, S., Salhab, N., et al.[2019]

Intravenous zoledronic acid has been shown to be an effective treatment for children with mild osteogenesis imperfecta (OI), leading to an increase in bone mineral density (BMD) z-scores over 2 years of treatment.

The treatment was associated with some side effects, including transient decreases in serum calcium and phosphate levels, and two cases of symptomatic hypocalcemia, indicating the need for careful monitoring during therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Zoledronic acid treatment in children with osteogenesis imperfecta. Vuorimies, I., Toiviainen-Salo, S., Hero, M., et al.[2022]

Sequential treatment with romosozumab followed by alendronate is a cost-effective option for postmenopausal women with severe osteoporosis, showing an increase of 0.089 quality-adjusted life years (QALYs) at an additional cost of €3002 compared to alendronate alone.

The analysis indicated a 97.9% probability that this sequential treatment is cost-effective, given the Swedish willingness-to-pay threshold of €60,000 per QALY, making it a promising strategy for reducing fracture risk in high-risk patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Söreskog, E., Lindberg, I., Kanis, JA., et al.[2021]

In a case study of a 64-year-old man with osteogenesis imperfecta (OI) and severe osteoporosis, treatment with romosozumab led to significant increases in bone mineral density (BMD) of 22.0% in the lumbar spine and 136.4% in the total hip after 12 months.

Romosozumab treatment was well-tolerated, with no severe adverse effects reported, suggesting it may be a safe and effective option for improving bone health in patients with osteoporosis due to OI.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report. Uehara, M., Nakamura, Y., Nakano, M., et al.[2022]

In a study of 175 postmenopausal osteoporosis patients over 12 months, romosozumab treatment significantly increased bone mineral density (BMD) similarly in both groups, whether or not they received active vitamin D supplementation.

While both groups showed comparable increases in BMD, the group receiving vitamin D had a smaller increase in a bone formation marker (P1NP) and a larger decrease in a bone resorption marker (TRACP-5b), suggesting that vitamin D may influence bone turnover without affecting overall BMD gains.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis. Kobayakawa, T., Miyazaki, A., Takahashi, J., et al.[2022]

Romosozumab, a newly approved treatment for osteoporosis in Japan, effectively increases bone mineral density and reduces fracture risk by stimulating bone formation and suppressing bone resorption.

The ARCH study showed that romosozumab is more effective than alendronate, but due to its reversible effects, patients will need to follow up with anti-resorptive therapy after treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Sequential treatment of osteoporosis with anti-sclerostin.] Inoue, D.[2019]

Bisphosphonates are generally safe and well-tolerated for treating osteoporosis, with the most common side effects being gastrointestinal discomfort and flu-like symptoms, while serious adverse events are rare.

Skeletal complications like osteonecrosis of the jaw and atypical fragility fractures are infrequent compared to the risk of osteoporotic fractures, suggesting that the benefits of bisphosphonates often outweigh these risks, especially in patients with a similar fracture risk as those in clinical trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adverse effects of bisphosphonates. Abrahamsen, B.[2022]

Bisphosphonates like pamidronate and clodronate are commonly used in cancer treatment, with newer options like ibandronate and zoledronate showing promise for shorter infusion times and potentially better patient compliance.

While intravenous administration is preferred for chemotherapy patients due to its effectiveness, oral bisphosphonates offer outpatient convenience despite lower absorption rates and possible digestive side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dosing regimens and main adverse events of bisphosphonates. Body, JJ.[2019]

Romosozumab is an effective treatment for severe osteoporosis in postmenopausal women, significantly reducing vertebral and clinical fracture risk compared to placebo and oral alendronate in pivotal phase III trials involving monthly doses over 12 months.

The treatment not only increased bone mineral density significantly but also maintained these benefits even after transitioning to other osteoporosis therapies, indicating its potential as a valuable option for women at high risk of fractures.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Romosozumab: A Review in Postmenopausal Osteoporosis. Paik, J., Scott, LJ.[2021]

Alendronate treatment over 2 years significantly improved bone mineral density in children with osteogenesis imperfecta (OI), with increases of 47.8% to 106.6% in the lumbar spine and 24% to 51.4% in forearm bones.

The treatment was found to be safe and well-tolerated, with no significant side effects reported, suggesting that alendronate could be a promising oral alternative to pamidronate for increasing bone density in OI patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Alendronate treatment in osteogenesis imperfecta. Madenci, E., Yilmaz, K., Yilmaz, M., et al.[2013]

Aminobisphosphonates have been effectively used for over 20 years to treat osteoporosis, with initial studies showing few adverse events.

Recent pharmacovigilance reports have identified various complications, some serious, particularly with high doses used in oncology and long-term treatment, raising safety concerns for osteoporosis patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Adverse effects of bisphosphonates]. Arboleya, L., Alperi, M., Alonso, S.[2011]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT05972551

NCT05972551 | Study to Evaluate Efficacy and Safety of ...

The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of ...

2.

sciencedirect.com

sciencedirect.com/science/article/pii/S2376060523001438

Osteoporosis Improved by Romosozumab Therapy in a ...

Our patient's improvement in BMD of the spine and right hip after romosozumab therapy was significant at a 95% confidence level, compared to treatment ...

3.

mayo.edu

mayo.edu/research/clinical-trials/cls-20558273

Study to Evaluate Efficacy and Safety of Romosozumab ...

The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical ...

4.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/34491363/

Efficacy of romosozumab for osteoporosis in a patient with ...

Bone formation markers increased, and bone resorption markers decreased at 12 months of the therapy. Neither hypocalcaemia nor any other severe ...

5.

amgentrials.com

amgentrials.com/study/?id=20200105

Study to Evaluate Efficacy and Safety of Romosozumab ...

The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of ...

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT04545554

NCT04545554 | Study to Evaluate Romosozumab in ...

The primary objective of this study is to evaluate the pharmacokinetics (PK) profile following multiple subcutaneous (SC) doses of romosozumab in children and ...

7.

journalbonefragility.com

journalbonefragility.com/wp-content/uploads/journal/2025/5.1/24-28.pdf

Romosozumab treatment in osteogenesis imperfecta type I

It is an effective and FDA-approved treatment for postmenopausal osteoporosis [15] and has been shown to sig- nificantly improve lumbar spine, total hip, and ...